Dohan, A., Gallix, B., Guiu, B., Le Malicot, K., Reinhold, C., Soyer, P., Bennouna, J., Ghiringhelli, F., Barbier, E., Boige, V., Taieb, J., Bouché, O., François, E., Phelip, J., Borel, C., Faroux, R., Seitz, J., Jacquot, S., Ben Abdelghani, M., Khemissa-Akouz, F., Genet, D., Jouve, J. L., Rinaldi, Y., Desseigne, F., Texereau, P., Suc, E., Lepage, C., Aparicio, T., & Hoeffel, C. (2020). early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut, 69(3), 531–539. http://access.bl.uk/ark:/81055/vdc_100137791406.0x00003f